A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia
Conclusion Our study found that the combination of GO with azacitidine is relatively well tolerated, with response rates similar to those with GO monotherapy at higher doses. Differences in the GO drug schedule, dose level, and frequency might explain the discrepant response rates between our study and others, suggesting that the optimal GO dose remains unclear, especially when combined with hypomethylating agent therapy. Micro-Abstract In view of the single-agent activity of azacitidine and gemtuzumab ozogamicin (GO) in patients with relapsed acute myeloid leukemia, we studied a combination strategy in a phase I/II trial ...
Source: Clinical Lymphoma Myeloma and Leukemia - March 21, 2018 Category: Cancer & Oncology Source Type: research

Various signaling pathways in multiple myeloma cells and the effects of treatment on these pathways
Publication date: Available online 17 March 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Ali Dehghanifard, Saeid Kaviani, Saeid Abroun, Mahshad Mehdizadeh, Sajedeh Saiedi, Amirhosein Maali, Sasan Ghaffari, Mehdi Azad Multiple myeloma (MM) results from malignancy in plasma cells and occurs at the ages over 50. MM is the second most common hematologic malignancy after non-Hodgkin lymphoma, which constitutes one percent of all malignancies. Despite the great advances in the discovery of useful drugs for this disease such as Dexamethasone (DEX) and Bortezomib (BTZ), it is still an incurable malignancy due to ...
Source: Clinical Lymphoma Myeloma and Leukemia - March 19, 2018 Category: Cancer & Oncology Source Type: research

Leukocytoclastic vasculitis and desensitization to high-dose methotrexate in primary central nervous system lymphoma
Publication date: Available online 19 March 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Colette Hanna, Diego Villa, Carla Irani, Marwan Ghosn, Elie El Rassy The backbone drug in the management of primary central nervous system lymphoma (PCNSL) is systemic high-dose methotrexate (HD MTX). This case report describes a previously healthy 56-year old man diagnosed with PCNSL who developed a severe leucocytoclastic vasculitis that was clinically consistent with HD MTX toxicity. He was given a premedication regimen along with a desensitization protocol for HD MTX that permitted the administration of additional...
Source: Clinical Lymphoma Myeloma and Leukemia - March 19, 2018 Category: Cancer & Oncology Source Type: research

Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem Cell Transplantation
Publication date: February 2018 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 2 Author(s): Andrea Tendas, Francesco Marchesi, Ombretta Annibali, Debora Saltarelli, Pasquale Niscola, Alessio Pio Perrotti, William Arcese (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Consolidation Radiation Therapy for Patients With Advanced Hodgkin Lymphoma in Complete Metabolic Response According to PET-CT or Gallium Imaging
Conclusion Low-dose RT, administered to all sites of original involvement, was associated with improved PFS, even in the setting of a metabolic CR after ABVD. Micro-Abstract The role of consolidation radiation therapy (RT) in advanced Hodgkin lymphoma is controversial, especially if a complete response (CR) is achieved according to positron emission tomography-computed tomography imaging after chemotherapy. In this series, low-dose (approximately 20 Gy) RT to all sites of original disease improved progression-free survival, even in the setting of a CR after ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine). Long-...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Azacitidine Use for Myeloid Neoplasms
Publication date: Available online 8 February 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Riad El Fakih, Rami Komrokji, Marwan Shaheen, Fahad Almohareb, Walid Rasheed, Mona Hassanein Azacitidine and decitabine are hypomethylating agents frequently used interchangeably to treat myeloid neoplasms in different settings. Azacitidine is metabolized intracellularly into decitabine. Hypomethylating agents work by inhibiting DNA methyltransferases, causing demethylation of aberrantly methylated promoter regions of genes involved in the pathogenesis of myeloid neoplasms. Azacitidine was the first agent approved b...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial
Conclusion In this study, we investigated the effect of pharmacogenetics in the context of a CML treatment discontinuation trial. The transcript levels of the efflux transporter ABCG2 predicted TFR after TKI discontinuation. Micro-Abstract Whithin the EURO-SKI trial, 132 chronic phase CML patients discontinued imatinib treatment. RNA was isolated from peripheral blood in order to analyze the expression of MDR1, ABCG2 and OCT1. ABCG2 was predictive for treatment-free remission in Cox regression analysis. High transcript levels of the ABCG2 efflux transporter (>4.5‰) were associated with a twofold higher r...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Outcomes of Adolescents and Young Adults With Acute Myeloid Leukemia Treated in a Single Latin American Center
Conclusion Low EFS and OS rates were found for AML patients in the AYA group. To improve survival rates, intensified chemotherapy regimens and early hematopoietic stem cell transplantation are needed. Micro-Abstract Hispanic patients aged < 40 years with a diagnosis of acute myeloid leukemia (AML) during 2003 to 2016 in Northeast Mexico were evaluated. The group included 46 children and 88 adolescents and young adults (AYAs) aged 15 to 39 years. A greater overall response rate was found in the children (87.2% vs. 69% in AYAs). Low event-free and overall survival rates for AYA patients with AML were documented. ...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Chronic Lymphocytic Leukemia: A Review of Front-line Treatment Options, With a Focus on Elderly CLL Patients
Publication date: Available online 8 February 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Alma O'Reilly, James Murphy, Sarah Rawe, Mary Garvey Chronic lymphocytic leukemia (CLL) remains the most prevalent form of leukemia in the Western world, with no cure to date. Ongoing and essential research into this heterogeneous disease has led to a number of new treatment options becoming available to CLL patients in the past decade. The present review presents the recent developments in the field of CLL treatment, with the main focus on elderly patients and CLL patients with coexisting comorbidities. The review ...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Publication date: Available online 8 February 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Jill A. Bell, Aaron Galaznik, Rachel Huelin, Michael Stokes, Yelan Guo, Robert J. Fram, Douglas V. Faller High-dose chemotherapy with allogeneic hematopoietic stem cell transplantation (allo-HSCT) can produce long-term remission in patients with higher-risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML). However, this treatment regimen is not appropriate for elderly and/or comorbid patients; in these cases, azacitidine is a standard treatment. This systematic review was conducted to ev...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma
Conclusion Our results are encouraging and justify evaluation of TECAM versus BEAM (carmustine, etoposide, cytarabine, melphalan) in a prospective multicenter study in a large homogenous patient population. Micro-Abstract High-dose chemotherapy and autologous stem cell transplantation (ASCT) is the current standard of care for relapsed lymphoma. We retrospectively analyzed the data from 212 lymphoma patients who had undergone ASCT with the TECAM conditioning regimen. The 3-year overall survival, progression-free survival, and death resulting from treatment were comparable to those reported with other conditioning regimens....
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

A Retrospective Study of Double-hit Lymphomas  in Elderly Patients (Aged  & gt;  70 Years): Overall Outcomes
Conclusion Although the numbers are small, elderly patients with DHL can achieve durable EFS and OS. Using the comprehensive geriatric assessment can aid in decision making in the treatment options for elderly patients. Our retrospective analysis, given a small sample size, suggests that intensive treatment regimens can be offered to elderly patients with DHL. Micro-Abstract Double-hit lymphoma can be an aggressive disease that is difficult to treat in the elderly population. We evaluated patients aged > 70 years and their outcomes after treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, p...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: A  Thirty-year Experience
Publication date: Available online 16 February 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Vittorio Stefoni, Alessandro Broccoli, Lisa Argnani, Elena Sabattini, Michele Cavo, Pier Luigi Zinzani (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Prognostic Prediction Model for Second Allogeneic Stem-Cell Transplantation in Patients With Relapsed Acute Myeloid Leukemia: Single-Center Report
Conclusion This prognostic model might be useful to make an appropriate decision for allo-SCT2 in relapsed AML after the first autologous or allogeneic stem-cell transplantation. Micro-Abstract Prognostic factors of second allogeneic stem-cell transplantation (allo-SCT2) in 78 patients with relapsed acute myeloid leukemia after first transplantation were explored. Factors included poor cytogenetic risk at diagnosis, circulating blast ≥ 20% at relapse, duration from first transplantation to relapse of < 9 months, and failure to achieve morpohologic complete remission after allo-SCT2. Prognostic model der...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Risk Factors Influencing Outcome of Acute Leukemia Patients Who Experience Relapse After Allogeneic Hematopoietic Stem-Cell Transplantation
Conclusion Survival of acute leukemia patients who experience relapse after allogeneic HSCT is poor, especially in elderly patients and those who do not experience remission after relapse treatment. Micro-Abstract In a study of 43 patients to assess the risk factors influencing relapse outcome after hematopoietic stem-cell transplantation in acute leukemia, older age and failure to experience complete remission (CR) after treatment were associated with inferior overall survival. Female sex, extramedullary relapse, and absence of postrelapse graft-versus-host disease (GVHD) were associated with lower CR; and absence of extr...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia
Conclusion Ponatinib plus chemotherapy might be associated with better outcomes than chemotherapy with earlier generation TKIs in patients with newly diagnosed Ph+ ALL. Micro-Abstract The complete molecular response (CMR) and overall survival (OS) in patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia treated with front-line chemotherapy plus ponatinib versus earlier generation tyrosine kinase inhibitors were compared in a meta-analysis and meta-regression. The patients treated with front-line ponatinib versus earlier generation treatments were more likely to achieve a CMR and had greater rates...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review
Publication date: Available online 17 February 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Charlotte Cosemans, Bénedith Oben, Ingrid Arijs, Annick Daniëls, Jeroen Declercq, Kimberly Vanhees, Guy Froyen, Brigitte Maes, Jeroen Mebis, Jean-Luc Rummens Multiple myeloma (MM), characterized by malignant plasma cells in the bone marrow, is consistently preceded by asymptomatic premalignant stage monoclonal gammopathy of undetermined significance (MGUS). These MGUS patients have an annual risk of 1% to progress to MM. Clinical, imaging, and genomic (genetic and epigenetic) factors were identified, wh...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses
Conclusion Abnormal HLC ratios and HLC-matched pair suppression can increase the sensitivity for detecting residual disease in patients with multiple myeloma with deep responses. Micro-Abstract Heavy/light chain (HLC) assay can quantify involved as well as uninvolved immunoglobulin pairs. We compared the sensitivity between HLC assay and other examinations in patients with multiple myeloma. The lower the monoclonal protein levels, the more the possibility that the patients had normal HLC ratios and no matched pair suppression. Abnormal HLC ratios and HLC-matched pair suppression can increase the sensitivity. (Source: Clini...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Prognostic Effect of CD20 Expression in Adult B-cell Acute Lymphoblastic Leukemia
Conclusion CD20 expression in adult ALL-B is associated with decreased OS. Treatment with rituximab can increase OS, EFS, and CR in the 18- to 39-year age group. Micro-Abstract Expression of CD20 in adult B-cell acute lymphoblastic leukemia has been associated with a poor prognosis. Previous studies have suggested treatment with rituximab can significantly improve event-free, although not overall, survival. The results from the present study of Hispanic ALL-B patients support the role of CD20 as a determinant of a poor prognosis and suggest that treatment with rituximab offers significant benefit. (Source: Clinical Lymphom...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

L-carnitine and vitamin B complex for the treatment of pegasparaginase-induced hyperbilirubinemia
Publication date: Available online 26 February 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Caitlin R. Rausch, Shilpa Paul, Kayleigh R. Marx, Elias Jabbour, Naveen Pemmaraju, Alessandra Ferrajoli, Hagop Kantarjian (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Thiotepa 10 mg/kg seems superior to Thiotepa 5 mg/kg in the TBF conditioning regimen in patients undergoing allogeneic stem cell transplantation
Conclusion Acknowledging the retrospective nature of our study, and the small sample size, these results suggest patients deemed fit to receive T10 based conditioning for allo-SCT in high risk HM had better OS and PFS than those who received T5 with no additional toxicities, Therefore patients should be stratified before conditioning those judged fit should receive T10, while the others should consider alternative RIC conditioning regimens. However, the effect of the total dose of Thiotepa on transplant outcomes needs to be confirmed in a larger study. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Multiple Myeloma: Clinical Updates from the American Society of Hematology Annual Meeting 2017
Publication date: Available online 1 March 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Evangelos Terpos The novel clinical data for myeloma that were presented in the 2017 Annual Meeting of the American Society of Hematology are summarized here. Studies with curative approach (CESAR) or prolonging progression-free survival (CENTAURUS) for high-risk smoldering multiple myeloma (SMM) patients are described. Updated data from large phase 3 studies for newly diagnosed MM (NDMM) patients who are eligible for autologous transplantation (ASCT; EMN02, MRC XI) are described along with the results of studies using...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation
Conclusion Even in the era of novel agents, t(4;14) remains a negative prognostic marker. Frontline autologous stem cell transplant remains as an essential tool when treating these high-risk patients, but further prospective randomized studies are needed to determine the most effective strategy for this patient group. Micro-Abstract This retrospective study analyzed the long-term outcome of 75 patients with t(4;14) multiple myeloma treated in a single center with frontline bortezomib-based treatment. Frontline autologous stem cell transplant following bortezomib-based induction was associated with better progression-free s...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies
Conclusions In the present retrospective study of data from the SEER–Medicare database, we found that age, health status, race, and socioeconomic status were associated with receipt of MM treatment. These factors have previously been linked to reduced usage of specific treatments for MM, such as stem cell transplantation. To the best of our knowledge, however, ours is the first study to show their association with the receipt of any MM therapy. Micro-Abstract Identifying populations of older adults with myeloma who receive no treatment could help mitigate disparities. Among 3800 patients with active myeloma in the SE...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple Myeloma
Conclusion MM was associated with significant workplace and functional impairment, high OOPCs, and frequent office visits. High medication adherence was associated with better outcomes across these domains. As survival for patients with MM improves, patient QoL should be considered to enhance these outcomes. Micro-Abstract It is unclear how medication adherence affects the burden of multiple myeloma (MM). Overall, 162 adults with MM completed an online survey. Better medication adherence related to less impairment to work productivity and functioning, lower out of pocket costs, and fewer office visits. With increased survi...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease
Conclusion The results of our study have shown that patients with < 20% cellularity and < 20% blasts on the D14 bone marrow assessment should continue observation until recovery rather than receive additional immediate therapy. Micro-Abstract In our single center retrospective study of day 14 bone marrow assessment in AML, we found cellularity to be a stronger predictor of response than blast percentage or receipt of re-induction chemotherapy. For patients with blast percent and cellularity. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Outcome of Chronic Myeloid Leukemia-Chronic Phase Patients Treated With Imatinib: A Local Experience
Conclusion After a median follow-up of 8 years, imatinib was found to induce long survival with manageable side effect in adult Saudi patients with CML-CP. Micro-Abstract Imatinib (Gleevec) was the first drug to target the breakpoint cluster region (BCR)-Abelson (ABL) tyrosine kinase and hence became the first line of therapy for patients with chronic myeloid leukemia. It provides a high rate of remission and survival benefits with minimal side effects. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Interim PET Response-adapted Strategy in Untreated Advanced Stage Hodgkin Lymphoma: Results of GOELAMS LH 2007 Phase 2 Multicentric Trial
Conclusion A PET-guided strategy with early salvage therapy and high-dose therapy/autologous stem cell transplantation for patients with interim PET–2-positive findings is safe and feasible and provide similar outcome as patients with a negative PET-2. Micro-Abstract Hodgkin lymphoma is a curable disease with outcomes depending on initial prognostic factors and interim treatment response. Here, we conducted a phase II trial in advanced stage Hodgkin lymphoma to assess the feasibility and efficacy of a positron emission tomography-adapted strategy with early salvage for poor metabolic responders. We show that this str...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Safety and Preliminary Efficacy of Vorinostat With  R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075)
Conclusion VOR combined with R-EPOCH was tolerable and seemingly efficacious in patients with aggressive HIV-NHL. Micro-Abstract We performed a phase I trial of vorinostat (VOR) given on days 1 to 5 with R-EPOCH (rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) in patients with aggressive HIV-associated non-Hodgkin lymphoma. VOR was tolerable at 300 mg and seemingly efficacious with chemotherapy with complete response rate of 83% and 1-year event-free survival of 83%. VOR did not significantly alter chemotherapy steady-state concentrations, CD4+ cell counts, or HIV viral l...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Pegylated Filgrastim Versus Filgrastim for Stem Cell Mobilization in Multiple Myeloma After Novel Agent Induction
Conclusion The present study has demonstrated that a single dose of pegfilgrastim is comparable to filgrastim in terms of the timing and efficacy of PBSC harvest and could potentially spare the patient 6 days of filgrastim injections. In addition, ours is the first study to compare these growth factors using vinorelbine/cyclophosphamide as mobilization chemotherapy. Micro-Abstract The current standard of care for transplant-eligible multiple myeloma (MM) patients is novel agent-based (NA) induction followed by high-dose chemotherapy and autologous stem cell transplant (ASCT). This study analyzed the efficacy of pegfilgrast...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

A Phase I/II Trial of the Combination Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia
Conclusion Our study found that the combination of GO with azacitidine is relatively well tolerated, with similar response rates to GO monotherapy at higher doses. Differences in GO drug schedule, dose level and frequency may explain discrepant response rates between our study and others, suggesting that the optimal GO dose remains unclear, especially when combined with HMA therapy. Teaser In view of the single-agent activity of azacitidine and gemtuzumab ozogamicin (GO) in patients with relapsed acute myeloid leukemia (AML), a combination strategy was studied in this phase I/II trial to potentially further improve outcome...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Treatment with JAK inhibitors in myelofibrosis patients nullifies the prognostic impact of unfavorable cytogenetics
Publication date: Available online 2 March 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Vincent T. Ma, Philip S. Boonstra, Kamal Menghrajani, Cecelia Perkins, Krisstina L. Gowin, Ruben A. Mesa, Jason R. Gotlib, Moshe Talpaz In the era before the advent of JAK inhibitors, cytogenetic information was used to predict survival in myelofibrosis patients. However, the prognostic value of cytogenetics in the setting of JAK inhibitor therapy remains unknown. We performed a retrospective analysis on 180 patients with bone marrow biopsy-proven myelofibrosis from three US academic medical centers. We fit Cox proport...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Elderly Patients (Age 70 Years Or Older) With Secondary Acute Myeloid Leukemia Or Acute Myeloid Leukemia Developed Concurrently To Another Malignant Disease
Conclusion Our results support that sAML and de novo AML in elderly patients are not prognostically distinct entities. They should therefore not be considered separately when investigating outcomes and new treatment strategies. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma
Conclusion Overall, data from PANEX support regulatory approval of panobinostat plus bortezomib and dexamethasone and suggest potential tolerability benefits of subcutaneous bortezomib in this regimen. Teaser The Panobinostat Expansion (PANEX) treatment protocol (N = 39) provided access to panobinostat and gathered additional efficacy and safety data on the panobinostat-bortezomib-dexamethasone regimen before commercial availability. The findings from the study supported those that led to regulatory approval of panobinostat-bortezomib-dexamethasone. Additionally, use of subcutaneous bortezomib in PANEX had potential tolera...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Clinical Implications of Targeting XPO1-Mediated Nuclear Export in Multiple Myeloma
Publication date: Available online 14 March 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Ujjawal H. Gandhi, William Senapedis, Erkan Baloglu, T.J. Unger, Ajai Chari, Dan Vogl, Robert F. Cornell Multiple myeloma (MM; myeloma) is a malignancy of plasma cells that is typically chronic, and relapse is common. Current therapeutic strategies include combination and sequential treatments with corticosteroids, alkylating agents, proteasomal inhibitors, immunomodulators, and monoclonal antibodies. These drugs prolong survival but ultimately become ineffective. Exportin 1 (XPO1), a nuclear export protein, is over-e...
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Treating Adult Acute Lymphoblastic Leukemia in Brazil – An increased early-mortality using a GMALL-based regimen
Conclusion Intensified chemotherapy protocols for adult ALL has succeeded in achieving better survival rates in the adults, especially the younger segment. Low overall survival found with GMALL in Brazil's public hospital denotes the importance of optimize the adaptations of international protocols for treatment of ALL in non-developed countries and, in parallel, improving supportive care in public services. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Tolerance, kinetics and depth of response for subcutaneous versus intravenous administration of bortezomib combination in Chinese newly diagnosed multiple myeloma patients
Conclusion SC Btz is associated with better tolerance; however, IV administration achieves a faster and deeper response in Chinese NDMM patients. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Serum free light chain difference and beta-2 microglobulin levels are risk factors for thromboembolic events in patients with AL amyloidosis
Conclusion The incidence of thromboembolism was substantial in AL amyloidosis. Higher FLC difference and B2MG levels were risk factors for thromboembolic events. Teaser AL amyloidosis may increase the risk for thromboembolism as well as other plasma cell dyscrasias. Therefore, we evaluated the features of thromboembolism in AL amyloidosis. The incidence of thromboembolism was substantial (12.3%); most events developed within the first year after diagnosis and arterial thromboembolism occurred frequently. Especially, patients with risk factors may require close monitoring for thromboembolism. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

Final 3-year results of the Dasatinib Discontinuation Trial in Patients with Chronic Myeloid Leukemia who received dasatinib as a second line treatment
Conclusion These findings suggest that discontinuation of second- or subsequent-line dasatinib after a sustained DMR of at least 1 year is feasible, particularly for patients with no prior history of imatinib resistance. In addition, the NK cell count was associated with TFR. (DADI trial; UMIN000005130). (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - March 15, 2018 Category: Cancer & Oncology Source Type: research

A Comparison of the Efficacy of Immunomodulatory-Containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis
Conclusion In patients with RRMM who are suitable for an IMiD-containing regimen, DRd has clear advantages in survival and response outcomes over other IMiD-containing regimens. Teaser A systematic review and network meta-analysis were conducted to compare the clinical efficacy of immunomodulatory drug–containing regimens in patients with RRMM. Daratumumab plus lenalidomide and dexamethasone had a significant advantage in improving progression-free survival in patients compared to other immunomodulatory-containing regimens. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 5, 2018 Category: Cancer & Oncology Source Type: research

Single center experience in treating patients with t(4;14) multiple myeloma with and without planned frontline autologous stem cell transplantation
Publication date: Available online 5 January 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Henry Chan, Madeline Phillips, Manjula Maganti, Sophia Farooki, Giovanni Piza Rodriguez, Esther Masih-Khan, Christine Chen, Anca Prica, Donna Reece, Rodger Tiedemann, Suzanne Trudel, Vishal Kukreti (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 5, 2018 Category: Cancer & Oncology Source Type: research

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States
Conclusion In a large database capturing a heterogeneous patient population and varied treatment patterns reflecting routine clinical care, we found a clinical benefit of continued longer DOT at first relapse. Despite the emerging paradigm favoring continuous therapy, second-line PFS (proxied by TTNT) was over 2-fold longer than DOT. Understanding barriers to extended duration of therapy may help improve outcomes in RRMM. Teaser Despite the emerging paradigm favoring continuous therapy, we report that in routine clinical care, myeloma patients at first relapse frequently discontinue treatment before progression, resulting ...
Source: Clinical Lymphoma Myeloma and Leukemia - January 5, 2018 Category: Cancer & Oncology Source Type: research

Pegylated Filgrastim vs. Filgrastim for Stem Cell Mobilization in Multiple Myeloma after Novel Agent Induction
This study focuses on the efficacy of pegfilgrastim in PBSC mobilization compared to filgrastim exclusively after novel agent-based induction in a homogeneous group of MM patients. We analyzed 89 patients with MM treated at two transplant centers in Singapore who received novel agent-based induction chemotherapy, PBSC mobilization with vinorelbine / cyclophosphamide, high-dose melphalan conditioning and autologous stem cell rescue. 61 patients were included in the pegfilgrastim group and 28 in the filgrastim group, with a similar median age and disease characteristics. PBSC harvesting was done at a similar median time of 9...
Source: Clinical Lymphoma Myeloma and Leukemia - January 5, 2018 Category: Cancer & Oncology Source Type: research

SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma
Publication date: Available online 4 January 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Marcus P. Watkins, Michelle A. Fanale, Nancy L. Bartlett Until recently, advances in classical Hodgkin lymphoma (HL) treatment primarily consisted of minor modifications of highly effective decades-old chemotherapy and radiation approaches. In early stage disease, excellent outcomes have been reported with fewer cycles of chemotherapy, lower doses and smaller radiation fields, and in some circumstances radiation elimination. In advanced stage disease, maintaining dose intensity of standard chemotherapy regimens has r...
Source: Clinical Lymphoma Myeloma and Leukemia - January 4, 2018 Category: Cancer & Oncology Source Type: research

HIV-Related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab
Publication date: Available online 3 January 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Elaine Chang, Gustavo Rivero, Niraj R. Patel, Elizabeth Y. Chiao, Syeling Lai, Kelash Bajaj, John E. Mbue, Sarvari V. Yellapragada (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - January 3, 2018 Category: Cancer & Oncology Source Type: research

Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma in Complete Metabolic Response by PET-CT or Gallium
Conclusions Low-dose RT, administered to all sites of original involvement, was associated with improved progression-free survival, even in the setting of a metabolic CR after ABVD. Teaser The role of consolidation radiation therapy (RT) in advanced Hodgkin lymphoma is controversial, especially if a complete response (CR) is achieved by PET-CT after chemotherapy. In this series, low-dose (∼20 Gy) RT to all sites of original disease improved progression-free survival, even in the setting of a CR after ABVD. Long-term toxicity was similar between chemotherapy and combined modality therapy. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - December 30, 2017 Category: Cancer & Oncology Source Type: research

Mechanisms of Hypercalcemia in non-Hodgkin Lymphoma and Associated Outcomes: a Retrospective Review
Conclusions The major mechanism by which non-Hodgkin lymphoma patients develop hypercalcemia is not mediated by calcitriol or PTHrP. Hypercalcemia is most prevalent in DLBCL patients of the non-germinal cell subtype. Patients with calcitriol-mediated hypercalcemia have a trend toward worse outcomes, suggesting that calcitriol may be a marker of high-grade lymphoma, transformation to such, or a surrogate for more advanced disease. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - December 30, 2017 Category: Cancer & Oncology Source Type: research

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study
Conclusion Lenalidomide did not adversely affect HRQoL in RBC-TD patients with lower-risk non-del(5q) MDS and response to lenalidomide was associated with significant improvements in HRQoL. Teaser HRQoL was evaluated among RBC-TD patients with lower-risk non-del(5q) MDS treated with lenalidomide (n = 160) or placebo (n = 79) in the phase 3 MDS-005 study. Lenalidomide did not worsen HRQoL; response to lenalidomide was associated with significant HRQoL improvement. Lenalidomide represents a treatment option for patients with lower-risk non-del(5q) MDS who are ineligible for or refractory to ESAs. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - December 30, 2017 Category: Cancer & Oncology Source Type: research

Cost-effectiveness of ibrutinib compared to obinutuzumab plus chlorambucil in untreated chronic lymphocytic leukemia patients with comorbidities in the United Kingdom
Conclusions As per base-case analyses, an adequate discount on ibrutinib is required to make it cost-effective as per the UK thresholds. The scenario analysis substantiates ibrutinib’s cost-savings for the UK National Health Services and advocates patient’s access to ibrutinib in the UK. Teaser A Markov model was used to assess the cost-effectiveness of ibrutinib compared to obinituzumab in combination with chlorambucil for untreated patients in the United Kingdom. The results demonstrated ibrutinib not to be cost-effective. However, additional analyses demonstrated ibrutinib to be significantly cost-effective ...
Source: Clinical Lymphoma Myeloma and Leukemia - December 29, 2017 Category: Cancer & Oncology Source Type: research

Should we Use Cell of Origin and Dual-Protein Expression in Treating DLBCL?
Publication date: Available online 24 December 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Peter A. Riedell, Sonali Smith Treatment outcomes in diffuse large B-cell lymphoma (DLBCL) following standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy is highly variable and dependent on a number of clinical, biologic, and genetic features. The identification of molecular heterogeneity via gene expression profiling dichotomizes patients based on the cell of origin (COO) model into germinal center B-cell like (GCB) and activated B-cell like (ABC) subsets, with ABC-DLBCL ...
Source: Clinical Lymphoma Myeloma and Leukemia - December 24, 2017 Category: Cancer & Oncology Source Type: research